New drug aims to stop dangerous transplant side effect
NCT ID NCT07246031
Summary
This study is testing whether adding an experimental drug called BPC2001 to standard care can better prevent a serious complication called graft-versus-host disease (GvHD) after a stem cell transplant. The trial will enroll 50 adults with blood cancers who are receiving a transplant from a partially matched family donor. Researchers will give six weekly doses of BPC2001 alongside standard medications to see if it safely reduces the risk of GvHD.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.